Biophan Announces Myotech CSS Data Presented at the Cleveland Clinic

Animal Study Results Presented at the 21st Century Treatment of Heart Failure Conference

PITTSFORD, NY--(Marketwire - October 19, 2007) - Biophan Technologies, Inc. (OTCBB: BIPH), a
developer of next-generation biomedical technology, today announced a
presentation of animal study data on the Myotech Circulatory Support System
(CSS) at the Cleveland Clinic's 21st Century Treatment of Heart Failure
Conference. The data presented indicates that the Myotech CSS holds
promise to vastly improve outcomes for patients with Congestive Heart
Failure (CHF).

Congestive Heart Failure affects an estimated 4.8 million Americans, and
half of all patients diagnosed with CHF will die within five years. There
are over 200,000 deaths per year related to CHF. Due to the poor prognosis
for patients with CHF, the search for better treatments is critically
important.

The Myotech CSS consists of a flexible polymer cup that slips over the
heart and connects to an external drive unit to pump the heart and restore
normal blood flow. It can be installed in approximately three minutes
through a small incision to provide immediate, life-saving support in
emergency situations. Since it has no contact with circulating blood, the
Myotech CSS also promises to reduce the risk of patient complications, such
as clotting and stroke, bleeding, and infection.

In the recently presented small-animal study, Myotech Chief Medical Officer
Dr. Mark Anstadt and his colleagues at Wright State University demonstrated
that the Myotech CSS effectively supported cardiac function when CHF had
been artificially induced. They also found evidence that the Myotech CSS
may one day revolutionize CHF treatment. One bio-marker that tracks cell
damage which might have been caused by the device was unchanged, indicating
the safety of the device to the heart muscle. Another marker that tracks
the gradual weakening of heart muscle as CHF progresses was drastically
reduced by use of the Myotech CSS, showing that this system could actually
reverse the course of CHF.

"This study indicates the tremendous potential for the Myotech CSS to treat
multiple forms of heart disease," stated John Lanzafame, Biophan CEO. "Our
initial focus is on acute circulatory support, which will be the initial
application of the technology, but this study shows that the Myotech CSS
may also be effective in treating CHF, and improving the quality of life
for thousands of patients. We are very excited about the long term
potential of this technology platform."

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and
competitive advantages to the medical device industry. The Company is
helping to commercialize the Myotech Circulatory Support System, which has
significant potential to improve the treatment of acute heart failure.
Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to
acquire additional equity, and is leading Myotech's business development
efforts. Biophan is traded on the OTC market under the symbol BIPH, and is
also listed on the Frankfurt Stock Exchange under the symbol BTN. For more
information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could differ
materially from the outcome or circumstance expressed or implied by such
forward-looking statements as a result of a variety of factors including,
but not limited to: Biophan's ability to develop its technologies; the
approval of Biophan's patent applications; the successful implementation of
Biophan's research and development programs; the ability of Biophan to
demonstrate the effectiveness of its technology; the acceptance by the
market of Biophan's technology and products incorporating such technology;
the ability of Biophan to effectively negotiate and enter into contracts
with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund
its operating and research and development activities until it generates
revenues sufficient to do so; and the timing of projects and trends in
future operating performance, as well as other factors expressed from time
to time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read in
conjunction with Biophan's periodic filings with the SEC, which are
incorporated herein by reference. The forward-looking statements contained
herein are made only as of the date of this press release, and Biophan
undertakes no obligation to publicly update such forward-looking statements
to reflect subsequent events or circumstances.